Description
Larotaxel (XRP9881) is a taxane analogue with preclinical activity against taxane-resistant breast cancer. Larotaxel (XRP9881) exerts its cytotoxic effect by promoting tubulin assembly and stabilizing microtubules, ultimately leading to cell death by apoptosis. It presents the ability to cross the blood brain barrier and has a much lower affinity for P-glycoprotein 1 than Docetaxel.
Product information
CAS Number: 156294-36-9
Molecular Weight: 831.90
Formula: C45H53NO14
Chemical Name: (1S,2S,3R,4S,7R,9S,11R,13R,16R)-4,13-bis(acetyloxy)-16-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-15,18,18-trimethyl-12-oxo-6-oxapentacyclo[12.3.1.0³,¹¹.0⁴,⁷.0⁹,¹¹]octadec-14-en-2-yl benzoate
Smiles: CC(C)(C)OC(=O)N[C@H]([C@@H](O)C(=O)O[C@@H]1C[C@@]2(O)[C@@H](OC(=O)C3C=CC=CC=3)[C@H]3[C@]4(C[C@H]4C[C@H]4OC[C@]43OC(C)=O)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)C1C=CC=CC=1
InChiKey: DXOJIXGRFSHVKA-DHQLGJJCSA-N
InChi: InChI=1S/C45H53NO14/c1-23-29(57-39(52)33(49)32(26-15-11-9-12-16-26)46-40(53)60-41(4,5)6)21-45(54)37(58-38(51)27-17-13-10-14-18-27)35-43(36(50)34(56-24(2)47)31(23)42(45,7)8)20-28(43)19-30-44(35,22-55-30)59-25(3)48/h9-18,28-30,32-35,37,49,54H,19-22H2,1-8H3,(H,46,53)/t28-,29-,30-,32+,33-,34-,35+,37+,43-,44+,45-/m1/s1
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: DMSO : ≥ 50 mg/mL (60.10 mM).
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.